Menopause hormone therapy linked to greater semaglutide weight loss in 3,900 women
Mayo Clinic Florida cohort found 11% weight loss at one year with hormone therapy plus semaglutide versus 9.5% with semaglutide alone.
MH
By Maren Holt · Senior Reporter, GLP-1
Oct 21 06:00 ETSource: Drugs.com
The wire
- 01Research set for presentation at the Menopause Society annual meeting followed about 2,400 women on semaglutide for roughly 26 months and 1,500 on tirzepatide for about 16 months.
- 02Clinicians prescribing incretins to postmenopausal patients may see differing response by hormone therapy status; 22% of combination users lost 20% or more body weight versus 18% on semaglutide alone.
- 03The effect was smaller with tirzepatide (6.6% versus 5.9% at three months), the work is an observational conference abstract, and lead author Regina Castaneda says more research is needed.
From the source
Read at drugs.comMenopause Hormone Therapy Might Boost GLP-1 Weight Loss Results, Study Says
WEDNESDAY, Oct. 21, 2026 — Hormone therapy for menopause might actually boost the weight-loss benefits of drugs like Ozempic and Zepbound, a new study says.Middle-aged women taking hormone therapy to manage hot flashes and other symptoms of...
